GMS health technology assessment最新文献

筛选
英文 中文
Differential diagnostic of the burnout syndrome. 倦怠综合征的鉴别诊断。
GMS health technology assessment Pub Date : 2010-07-05 DOI: 10.3205/hta000087
Dieter Korczak, Beate Huber, Christine Kister
{"title":"Differential diagnostic of the burnout syndrome.","authors":"Dieter Korczak,&nbsp;Beate Huber,&nbsp;Christine Kister","doi":"10.3205/hta000087","DOIUrl":"https://doi.org/10.3205/hta000087","url":null,"abstract":"<p><strong>Introduction: </strong>There is no consistent definition of burnout. It is neither a defined diagnosis in ICD-10 nor in DSM-IV. Yet it is diagnosed by office-based doctors and clinicians. Mainly due to reimbursement reasons, diagnoses like depression are used instead of burnout diagnoses. Therefore burnout has a very high individual, social and economic impact.</p><p><strong>Objectives: </strong>How is burnout diagnosed? Which criteria are relevant? How valid and reliable are the used tools?What kind of disorders in case of burnout are relevant for a differential diagnosis?What is the economic effect of a differential diagnosis for burnout?Are there any negative effects of persons with burnout on patients or clients?Can stigmatization of burnout-patients or -clients be observed?</p><p><strong>Methods: </strong>Based on a systematic literature research in 36 databases, studies in English or German language, published since 2004, concerning medical and differential diagnoses, economic impact and ethical aspects of burnout, are included and evaluated.</p><p><strong>Results: </strong>852 studies are identified. After considering the inclusion and exclusion criteria and after reviewing the full texts, 25 medical and one ethical study are included. No economic study met the criteria. The key result of this report is that so far no standardized, general and international valid procedure exists to obtain a burnout diagnosis. At present, it is up to the physician's discretion to diagnose burnout. The overall problem is to measure a phenomenon that is not exactly defined. The current available burnout measurements capture a three dimensional burnout construct. But the cutoff points do not conform to the standards of scientifically valid test construction. It is important to distinguish burnout from depression, alexithymia, feeling unwell and the concept of prolonged exhaustion. An intermittent relation of the constructs is possible. Furthermore, burnout goes along with various ailments like sleep disturbance. Through a derogation of work performance it can have also negative effects on significant others (for example patients). There is no evidence for stigmatization of persons with burnout.</p><p><strong>Discussion: </strong>The evidence of the majority of the studies is predominantly low. Most of the studies are descriptive and explorative. Self-assessment tools are mainly used, overall the Maslach Burnout Inventory (MBI). Objective data like medical parameters, health status, sick notes or judgements by third persons are extremely seldomly included in the studies. The sample construction is coincidental in the majority of cases, response rates are often low. Almost no longitudinal studies are available. There are insufficient results on the stability and the duration of related symptoms. The ambiguity of the burnout diagnosis is regularly neglected in the studies.</p><p><strong>Conclusions: </strong>The authors conclude, that (1) further rese","PeriodicalId":89142,"journal":{"name":"GMS health technology assessment","volume":"6 ","pages":"Doc09"},"PeriodicalIF":0.0,"publicationDate":"2010-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3205/hta000087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29645013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 68
Comparison of tools for assessing the methodological quality of primary and secondary studies in health technology assessment reports in Germany. 德国卫生技术评估报告中用于评估初级和二级研究方法学质量的工具的比较。
GMS health technology assessment Pub Date : 2010-06-14 DOI: 10.3205/hta000085
Maren Dreier, Birgit Borutta, Jona Stahmeyer, Christian Krauth, Ulla Walter
{"title":"Comparison of tools for assessing the methodological quality of primary and secondary studies in health technology assessment reports in Germany.","authors":"Maren Dreier,&nbsp;Birgit Borutta,&nbsp;Jona Stahmeyer,&nbsp;Christian Krauth,&nbsp;Ulla Walter","doi":"10.3205/hta000085","DOIUrl":"https://doi.org/10.3205/hta000085","url":null,"abstract":"<p><strong>Unlabelled: </strong>HEALTH CARE POLICY BACKGROUND: Findings from scientific studies form the basis for evidence-based health policy decisions.</p><p><strong>Scientific background: </strong>Quality assessments to evaluate the credibility of study results are an essential part of health technology assessment reports and systematic reviews. Quality assessment tools (QAT) for assessing the study quality examine to what extent study results are systematically distorted by confounding or bias (internal validity). The tools can be divided into checklists, scales and component ratings.</p><p><strong>Research questions: </strong>What QAT are available to assess the quality of interventional studies or studies in the field of health economics, how do they differ from each other and what conclusions can be drawn from these results for quality assessments?</p><p><strong>Methods: </strong>A systematic search of relevant databases from 1988 onwards is done, supplemented by screening of the references, of the HTA reports of the German Agency for Health Technology Assessment (DAHTA) and an internet search. The selection of relevant literature, the data extraction and the quality assessment are carried out by two independent reviewers. The substantive elements of the QAT are extracted using a modified criteria list consisting of items and domains specific to randomized trials, observational studies, diagnostic studies, systematic reviews and health economic studies. Based on the number of covered items and domains, more and less comprehensive QAT are distinguished. In order to exchange experiences regarding problems in the practical application of tools, a workshop is hosted.</p><p><strong>Results: </strong>A total of eight systematic methodological reviews is identified as well as 147 QAT: 15 for systematic reviews, 80 for randomized trials, 30 for observational studies, 17 for diagnostic studies and 22 for health economic studies. The tools vary considerably with regard to the content, the performance and quality of operationalisation. Some tools do not only include the items of internal validity but also the items of quality of reporting and external validity. No tool covers all elements or domains. Design-specific generic tools are presented, which cover most of the content criteria.</p><p><strong>Discussion: </strong>The evaluation of QAT by using content criteria is difficult, because there is no scientific consensus on the necessary elements of internal validity, and not all of the generally accepted elements are based on empirical evidence. Comparing QAT with regard to contents neglects the operationalisation of the respective parameters, for which the quality and precision are important for transparency, replicability, the correct assessment and interrater reliability. QAT, which mix items on the quality of reporting and internal validity, should be avoided.</p><p><strong>Conclusions: </strong>There are different, design-specific tools availa","PeriodicalId":89142,"journal":{"name":"GMS health technology assessment","volume":"6 ","pages":"Doc07"},"PeriodicalIF":0.0,"publicationDate":"2010-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d5/0a/HTA-06-07.PMC3010881.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29646270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Invasive home mechanical ventilation, mainly focused on neuromuscular disorders. 有创家庭机械通气,主要针对神经肌肉疾病。
GMS health technology assessment Pub Date : 2010-06-14 DOI: 10.3205/hta000086
Jens Geiseler, Ortrud Karg, Sandra Börger, Kurt Becker, Andreas Zimolong
{"title":"Invasive home mechanical ventilation, mainly focused on neuromuscular disorders.","authors":"Jens Geiseler,&nbsp;Ortrud Karg,&nbsp;Sandra Börger,&nbsp;Kurt Becker,&nbsp;Andreas Zimolong","doi":"10.3205/hta000086","DOIUrl":"https://doi.org/10.3205/hta000086","url":null,"abstract":"<p><strong>Introduction and background: </strong>Invasive home mechanical ventilation is used for patients with chronic respiratory insufficiency. This elaborate and technology-dependent ventilation is carried out via an artificial airway (tracheal cannula) to the trachea. Exact numbers about the incidence of home mechanical ventilation are not available. Patients with neuromuscular diseases represent a large portion of it.</p><p><strong>Research questions: </strong>Specific research questions are formulated and answered concerning the dimensions of medicine/nursing, economics, social, ethical and legal aspects. Beyond the technical aspect of the invasive home, mechanical ventilation, medical questions also deal with the patient's symptoms and clinical signs as well as the frequency of complications. Economic questions pertain to the composition of costs and the differences to other ways of homecare concerning costs and quality of care. Questions regarding social aspects consider the health-related quality of life of patients and caregivers. Additionally, the ethical aspects connected to the decision of home mechanical ventilation are viewed. Finally, legal aspects of financing invasive home mechanical ventilation are discussed.</p><p><strong>Methods: </strong>Based on a systematic literature search in 2008 in a total of 31 relevant databases current literature is viewed and selected by means of fixed criteria. Randomized controlled studies, systematic reviews and HTA reports (health technology assessment), clinical studies with patient numbers above ten, health-economic evaluations, primary studies with particular cost analyses and quality-of-life studies related to the research questions are included in the analysis.</p><p><strong>Results and discussion: </strong>Invasive mechanical ventilation may improve symptoms of hypoventilation, as the analysis of the literature shows. An increase in life expectancy is likely, but for ethical reasons it is not confirmed by premium-quality studies. Complications (e. g. pneumonia) are rare. Mobile home ventilators are available for the implementation of the ventilation. Their technical performance however, differs regrettably. Studies comparing the economic aspects of ventilation in a hospital to outpatient ventilation, describe home ventilation as a more cost-effective alternative to in-patient care in an intensive care unit, however, more expensive in comparison to a noninvasive (via mask) ventilation. Higher expenses arise due to the necessary equipment and the high expenditure of time for the partial 24-hour care of the affected patients through highly qualified personnel. However, none of the studies applies to the German provisionary conditions. The calculated costs strongly depend on national medical fees and wages of caregivers, which barely allows a transmission of the results. The results of quality-of-life studies are mostly qualitative. The patient's quality of life using mechanical ventilation ","PeriodicalId":89142,"journal":{"name":"GMS health technology assessment","volume":"6 ","pages":"Doc08"},"PeriodicalIF":0.0,"publicationDate":"2010-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/cf/HTA-06-08.PMC3010883.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29646271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Dental indications for the instrumental functional analysis in additional consideration of health-economic aspects. 牙科指征的仪器功能分析,在额外考虑健康经济方面。
GMS health technology assessment Pub Date : 2010-04-27 DOI: 10.3205/hta000084
Peter Tinnemann, Yvonne Stöber, Stephanie Roll, Christoph Vauth, Stefan N Willich, Wolfgang Greiner
{"title":"Dental indications for the instrumental functional analysis in additional consideration of health-economic aspects.","authors":"Peter Tinnemann,&nbsp;Yvonne Stöber,&nbsp;Stephanie Roll,&nbsp;Christoph Vauth,&nbsp;Stefan N Willich,&nbsp;Wolfgang Greiner","doi":"10.3205/hta000084","DOIUrl":"https://doi.org/10.3205/hta000084","url":null,"abstract":"<p><strong>Background: </strong>Besides clinical and radiological examination instrumental functional analyses are performed as diagnostic procedures for craniomandibular dysfunctions. Instrumental functional analyses cause substantial costs and shows a considerable variability between individual dentist practices.</p><p><strong>Objectives: </strong>On the basis of published scientific evidence the validity of the instrumental functional analysis for the diagnosis of craniomandibular dysfunctions compared to clinical diagnostic procedures; the difference of the various forms of the instrumental functional analysis; the existence of a dependency on additional other factors and the need for further research are determined in this report. In addition, the cost effectiveness of the instrumental functional analysis is analysed in a health-policy context, and social, legal and ethical aspects are considered.</p><p><strong>Methods: </strong>A literature search is performed in over 27 databases and by hand. Relevant companies and institutions are contacted concerning unpublished studies. The inclusion criteria for publications are (i) diagnostic studies with the indication \"craniomandibular malfunction\", (ii) a comparison between clinical and instrumental functional analysis, (iii) publications since 1990, (iv) publications in English or German. The identified literature is evaluated by two scientists regarding the relevance of content and methodical quality.</p><p><strong>Results: </strong>The systematic database search resulted in 962 hits. 187 medical and economic complete publications are evaluated. Since the evaluated studies are not relevant enough to answer the medical or health economic questions no study is included.</p><p><strong>Discussion: </strong>The inconsistent terminology concerning craniomandibular dysfunctions and instrumental functional analyses results in a broad literature search in databases and an extensive search by hand. Since no relevant results concerning the validity of the instrumental functional analysis in comparison to the clinical functional analysis are found, it is impossible to make relevant statements concerning the underlying research questions.</p><p><strong>Conclusion: </strong>Studies comparing the instrumental functional analysis to the clinical functional analysis for the diagnosis of craniomandibular dysfunctions are missing. So far the instrumental functional analysis is not systematically and independently validated in comparison to the clinical functional analysis as the reference standard. It is uncertain, whether conducting an instrumental functional analysis with a clinical functional analysis for the diagnostics of craniomandibular dysfunctions is recommendable. Further research is strongly recommended.</p>","PeriodicalId":89142,"journal":{"name":"GMS health technology assessment","volume":"6 ","pages":"Doc06"},"PeriodicalIF":0.0,"publicationDate":"2010-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/27/HTA-06-06.PMC3010889.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29646269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. 决策分析模型评估HPV-DNA检测在德国原发性宫颈癌筛查中的长期有效性和成本效益。
GMS health technology assessment Pub Date : 2010-04-27 DOI: 10.3205/hta000083
Gaby Sroczynski, Petra Schnell-Inderst, Nikolai Mühlberger, Katharina Lang, Pamela Aidelsburger, Jürgen Wasem, Thomas Mittendorf, Jutta Engel, Peter Hillemanns, Karl Ulrich Petry, Alexander Krämer, Uwe Siebert
{"title":"Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.","authors":"Gaby Sroczynski,&nbsp;Petra Schnell-Inderst,&nbsp;Nikolai Mühlberger,&nbsp;Katharina Lang,&nbsp;Pamela Aidelsburger,&nbsp;Jürgen Wasem,&nbsp;Thomas Mittendorf,&nbsp;Jutta Engel,&nbsp;Peter Hillemanns,&nbsp;Karl Ulrich Petry,&nbsp;Alexander Krämer,&nbsp;Uwe Siebert","doi":"10.3205/hta000083","DOIUrl":"https://doi.org/10.3205/hta000083","url":null,"abstract":"<p><strong>Background: </strong>Persistent infections with high-risk types of human papillomavirus (HPV) are associated with the development of cervical neoplasia. Compared to cytology HPV testing is more sensitive in detecting high-grade cervical cancer precursors, but with lower specificity. HPV based primary screening for cervical cancer is currently discussed in Germany. Decisions should be based on a systematic evaluation of the long-term effectiveness and cost-effectiveness of HPV based primary screening.</p><p><strong>Research questions: </strong>What is the long-term clinical effectiveness (reduction in lifetime risk of cervical cancer and death due to cervical cancer, life years gained) of HPV testing and what is the cost-effectiveness in Euro per life year gained (LYG) of including HPV testing in primary cervical cancer screening in the German health care context? How can the screening program be improved with respect to test combination, age at start and end of screening and screening interval and which recommendations should be made for the German health care context?</p><p><strong>Methods: </strong>A previously published and validated decision-analytic model for the German health care context was extended and adapted to the natural history of HPV infection and cervical cancer in order to evaluate different screening strategies that differ by screening interval, and tests, including cytology alone, HPV testing alone or in combination with cytology, and HPV testing with cytology triage for HPV-positive women. German clinical, epidemiological and economic data were used. In the absence of individual data, screening adherence was modelled independently from screening history. Test accuracy data were retrieved from international meta-analyses. Predicted outcomes included reduction in lifetime-risk for cervical cancer cases and deaths, life expectancy, lifetime costs, and discounted incremental cost-effectiveness ratios (ICER). The perspective of the third party payer and 3% annual discount rate were adopted. Extensive sensitivity analyses were performed in order to evaluate the robustness of results and identify areas of future research.</p><p><strong>Results: </strong>In the base case analysis screening resulted in a 53% to 97% risk reduction for cervical cancer with a discounted ICER between 2,600 Euro/LYG (cytology alone every five years) and 155,500 Euro/LYG (Annual cytology age 20 to 29 years, and annual HPV age 30 years and older). Annual cytology, the current recommended screening strategy in Germany, was dominated. In sensitivity analyses variation in the relative increase in the sensitivity of HPV testing as compared to cytology, HPV test costs, screening adherence, HPV incidence, and annual discount rate influenced the ICER results. Variation in the screening start age also influenced the ICER. All cytology strategies were dominated by HPV screening strategies, when relative sensitivity increase by HPV testing compared to cytolo","PeriodicalId":89142,"journal":{"name":"GMS health technology assessment","volume":"6 ","pages":"Doc05"},"PeriodicalIF":0.0,"publicationDate":"2010-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/d1/HTA-06-05.PMC3010885.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29646268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Specific immunotherapy (SIT) in the treatment of allergic rhinitis. 特异性免疫疗法(SIT)治疗变应性鼻炎。
GMS health technology assessment Pub Date : 2010-03-16 DOI: 10.3205/hta000079
Anja Hagen, Vitali Gorenoi, Matthias P Schönermark
{"title":"Specific immunotherapy (SIT) in the treatment of allergic rhinitis.","authors":"Anja Hagen,&nbsp;Vitali Gorenoi,&nbsp;Matthias P Schönermark","doi":"10.3205/hta000079","DOIUrl":"https://doi.org/10.3205/hta000079","url":null,"abstract":"<p><strong>Scientific background: </strong>Allergic rhinitis (AR) exhibits a prevalence of approx. 20% in Germany and causes enormous costs in the health care system. Specific immunotherapy (SIT) is considered to be the only potentially causal therapy for AR and mainly administered by two routes, subcutaneous (SCIT) and sublinguale (SLIT). SIT promises a reduction of symptoms and the need for medication in patients with AR.</p><p><strong>Research questions: </strong>The question arises, to what extent is SIT effective and cost effective in the treatment of AR and which ethical-social and legal aspects have to be considered regarding its application.</p><p><strong>Methods: </strong>The literature search was accomplished in the electronic data bases MEDLINE, EMBASE etc. in February 2008. The medical evaluation was based on systematic reviews of blinded, randomised controlled studies (RCT). The economic evaluation included health-economic studies on the basis of RCT. Additionally, it was also searched for publications explicitly addressing ethical-social and legal aspects of the use of SIT.</p><p><strong>Results: </strong>MEDICAL EVALUATION: Two reviews on SCIT and three on SLIT were included in the medical evaluation. For the evaluation of SIT with grass pollen results for short and medium-term effects are considered from several studies, for SIT with other seasonal allergens (e. g. tree pollen) and with house dust mite allergens from clearly fewer studies and for SIT with other perennial allergens only from a few. The reviews report a significant reduction of the symptom and medication score in favour of SCIT with seasonal allergens and recognise the effectiveness at least for grass pollen allergens. Also for other seasonal allergens SCIT is appraised as effective. The reviews about SLIT determine a significant reduction of the symptom and the medication score in favour of SLIT vs. placebo in short and medium term follow-up in evaluations across all allergens. The subgroup analyses show a significant reduction of the symptom and medication score only in favour of SLIT with seasonal allergens. HEALTH ECONOMIC EVALUATION: Four publications about two health economic studies are identified, one of these publications on Alutard-SQ(®) injections (SCIT) and three on GRAZAX(®) tablets (SLIT). The studies provide more (on Alutard-SQ(®)) or less (on GRAZAX(®)) robust information, but no evidence on cost effectiveness of these SIT administration forms in patients with AR.</p><p><strong>Discussion: </strong>The topic of the report is very broad, so that the evidence is summarised using systematic reviews. In particular the statistic heterogeneity of the studies found in the reviews considerably limits the strength of the findings. The included health economic studies show different methodical flaws, the largest potential bias is the projection of the magnitude of the medium-term clinical effects on the time period of nine years.</p><p><strong>Conclusions: </s","PeriodicalId":89142,"journal":{"name":"GMS health technology assessment","volume":"6 ","pages":"Doc01"},"PeriodicalIF":0.0,"publicationDate":"2010-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f1/c4/HTA-06-01.PMC3010882.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29646264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Medical and health economic evaluation of prevention- and control measures related to MRSA infections or -colonisations at hospitals. 医院MRSA感染或定植相关防控措施的医学和卫生经济评价
GMS health technology assessment Pub Date : 2010-03-16 DOI: 10.3205/hta000082
Dieter Korczak, Christine Schöffmann
{"title":"Medical and health economic evaluation of prevention- and control measures related to MRSA infections or -colonisations at hospitals.","authors":"Dieter Korczak,&nbsp;Christine Schöffmann","doi":"10.3205/hta000082","DOIUrl":"https://doi.org/10.3205/hta000082","url":null,"abstract":"<p><strong>Introduction: </strong>Methicillin-resistant Staphylococcus aureus (MRSA) are dangerous agents of nosocomial infections. In 2007 the prevalence of MRSA is 20.3% in Germany (Oxacilline-resistance according to EUCAST-criteria [EUCAST = European Committee on Antimicrobial Susceptibility Testing]).</p><p><strong>Objectives: </strong>Which measurements are effective in the prevention and control of MRSA-infections in the hospital?How effective are contact precautions, screening, decolonisation, education and surveillance?Which recommendations can be given to health care politics on the basis of cost-effectiveness studies?Have there been any adverse effects on patients and clinical staff?What kind of liability problems exist?</p><p><strong>Methods: </strong>Based on a systematic review of the literature studies are included which have been published in German or English language since 2004.</p><p><strong>Results: </strong>1,508 articles have been found. After having surveyed the full text, 33 medical, eight economic and four ethical/juridical studies are included for the Health Technology Assessment (HTA) report. The key result of the HTA report is that different measurements are effective in the prevention and control of MRSA-infections in hospitals, though the majority of the studies has a low quality. Effective are the conduction of differentiated screening measurements if they take into account the specific endemic situation, the use of antibiotic-control programs and the introduction and control of hygienic measurements. The break even point of preventive and control measurements cannot be defined because the study results differ too much. In the future it has to be more considered that MRSA-infections and contact precautions lead to a psycho-social strain for patients.</p><p><strong>Discussion: </strong>It is hardly possible to describe causal efficacies because in the majority of the studies confounders are not sufficiently considered. In many cases bundles of measurements have been established but not analyzed individually. The internal and external validity of the studies is too weak to evaluate single interventions. Hygienic measurements prove to be effective in combination with other measurements. But it cannot be said which of the single measurements (gloves, washing hands, wearing gowns or masks) has the strongest effect on the reduction of MRSA. It is irritating that there are high differences in the compliance concerning hand hygiene between different studies. A general decolonisation is questionable for different reasons: first because of the side-effects for patients, second because of the high rate of spontaneous remissions in the untreated control group, third because of the differentiated process from colonisation to infection. Severalfold Hawthorne effects have been reported. One of them is that the competition between hospitals to reduce MRSA-rates leads already to a reduction.</p><p><strong>Conclusions: </strong>It is ","PeriodicalId":89142,"journal":{"name":"GMS health technology assessment","volume":"6 ","pages":"Doc04"},"PeriodicalIF":0.0,"publicationDate":"2010-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/04/HTA-06-04.PMC3010887.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29646267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 22
The impact of microsurgery, stereotactic radiosurgery and radiotherapy in the treatment of meningiomas depending on different localizations. 显微外科、立体定向放射外科和放疗在脑膜瘤治疗中的作用取决于不同的定位。
GMS health technology assessment Pub Date : 2010-03-16 DOI: 10.3205/hta000080
Kirsten Schmieder, Martin Engelhardt, Sebastian Wawrzyniak, Sandra Börger, Kurt Becker, Andreas Zimolong
{"title":"The impact of microsurgery, stereotactic radiosurgery and radiotherapy in the treatment of meningiomas depending on different localizations.","authors":"Kirsten Schmieder,&nbsp;Martin Engelhardt,&nbsp;Sebastian Wawrzyniak,&nbsp;Sandra Börger,&nbsp;Kurt Becker,&nbsp;Andreas Zimolong","doi":"10.3205/hta000080","DOIUrl":"https://doi.org/10.3205/hta000080","url":null,"abstract":"<p><strong>Scientific background: </strong>Meningiomas are the most common benign intracranial neoplasms with a slow growth presented as the intracranial lesion. These tumors are without any symptoms for a long time. At the time of diagnosis it is frequently an asymptomatic tumor. In that case the therapist may well suggest a wait-and-see strategy. The therapy of meningiomas focuses firstly on the microsurgical treatment. Volume reduction can be achieved immediately after treatment. Stereotactic radiosurgery is an important non-invasive treatment option for recurrent tumors or meningiomas with partial resection. The technical equipment for the stereotactic radiosurgery is a cost intensive investment. In this context the high precision of the intervention, presented as a low invasiveness of the treatment, is an important factor. The aim of this assessment is to identify the chances and limitations of the diverse treatment options and to estimate their outcome for different localisations of meningiomas.</p><p><strong>Methods: </strong>In December 2007 a systematic literature search was conducted using the most relevant medical databases. The whole strategy and the used search terms were documented. The literature search was supplemented with an internet and literature based hand search on law, ethics and economics. Primary studies and systematic reviews which report relevant outcomes are included in this analysis. The current assessment is based on the available evidence that was found at the time of the literature search.</p><p><strong>Results: </strong>A total of 31 publications for the medical focus of assessment and three reports from the economical hand search were included. In general, it is not possible to identify neither randomised clinical trials or prospective, contrasting cohort studies nor studies summarising results from such studies. The results presented in the literature published by surgeons strongly vary regarding localisation of meningiomas. Publications not differentiating between the localisation of meningiomas indicate a progression free survival rate of five years in 77 to 97% of the cases after complete surgical resection of the tumor, in 18 to 70% of the cases after subtotal resection and for patients who had undergone surgical resection and a combined radiotherapeutical treatment of their meningiomas a five year progression free survival rate between 82 and 97%. Other treatment options like hormone therapy or treatments to stop tumor growth had been used unsuccessfully so far. Based on the results presented regarding economic evaluation, costs resulting from radiosurgical treatment are lower in contrast to costs resulting from surgical resection. However, it has to be taken into account that costs resulting from radiosurgical treatment strongly depend on the number of patients treated in total with the radiosurgical equipment.</p><p><strong>Conclusion: </strong>Due to the strong dependencies between the results from surgi","PeriodicalId":89142,"journal":{"name":"GMS health technology assessment","volume":"6 ","pages":"Doc02"},"PeriodicalIF":0.0,"publicationDate":"2010-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/58/84/HTA-06-02.PMC3010884.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29646265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
New-onset diabetes and antihypertensive treatment. 新发糖尿病与降压治疗。
GMS health technology assessment Pub Date : 2010-03-16 DOI: 10.3205/hta000081
Christine Grimm, Juliane Köberlein, Waldemar Wiosna, Jutta Kresimon, Peter Kiencke, Reinhard Rychlik
{"title":"New-onset diabetes and antihypertensive treatment.","authors":"Christine Grimm,&nbsp;Juliane Köberlein,&nbsp;Waldemar Wiosna,&nbsp;Jutta Kresimon,&nbsp;Peter Kiencke,&nbsp;Reinhard Rychlik","doi":"10.3205/hta000081","DOIUrl":"https://doi.org/10.3205/hta000081","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic diseases substantially contribute to the continuous increase in health care expenditures, including type-2 diabetes mellitus as one of the most expensive chronic diseases. Arterial hypertension presents a risk factor for the development of type-2 diabetes mellitus. Numerous analyses have demonstrated that antihypertensive therapies promote the development of type-2-diabetes mellitus. Studies indicate, that the application of angiotensin converting enzyme (ACE) inhibitors and angiotensin-receptor-blockers (ARB) lead to less new-onset diabetes compared to beta-blockers, diuretics and placebo. Given that beta-blockers and diuretics impair the glucose metabolism, the metabolic effects of different antihypertensive drugs should be regarded; otherwise not only the disease itself, but also antihypertensive therapies may promote the development of new-onset diabetes. Even though, the cost of ACE inhibitors and ARB are higher, the use in patients with metabolic disorders could be cost-effective in the long-term if new-onset diabetes is avoided.</p><p><strong>Objectives: </strong>To evaluate which class of antihypertensive agents promote the development or the manifestation of type-2 diabetes mellitus. How high is the incidence of new-onset diabetes during antihypertensive therapy and how is treatment-induced type-2 diabetes mellitus evaluated clinically? Which agents are therefore cost-effective in the long term? Which ethical, social or legal aspects should be regarded?</p><p><strong>Methods: </strong>A systematic literature review was conducted including clinical trials with at least ten participants which reported new-onset diabetes in the course of antihypertensive treatment. The trials had to be published after 1966 (after 2003 for economic publications) in English or German.</p><p><strong>Results: </strong>A total of 34 clinical publications meet the inclusion criteria. Of these, eight publications focus on the development of diabetes mellitus under treatment with diuretic and/or beta-blockers, six publications focused on ACE inhibitors alone or in combination with calcium-channel-blockers, ten publications on ARB and/or ACE inhibitors with respect to their effects on new-onset diabetes or their preventive aspects. Furthermore, five publications investigate the role of calcium-channel-antagonists in the development of diabetes, and five publications indicate the development of new-onset diabetes with different antihypertensive agents amongst each other or in comparison to no antihypertensive treatment. The clinical trials show a significant difference in the development of new-onset diabetes. Therapies with diuretics and/or beta-blockers result in a higher incidence of new-onset diabetes. ARB as well as ACE inhibitors have a preventive effect and calcium-channel-blockers show a neutral position regarding the development of new-onset diabetes. Two publications report on economic results. The first one evaluat","PeriodicalId":89142,"journal":{"name":"GMS health technology assessment","volume":"6 ","pages":"Doc03"},"PeriodicalIF":0.0,"publicationDate":"2010-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/e0/HTA-06-03.PMC3010880.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29646266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 26
Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease. 冠心病非药物二级预防的医疗卫生经济效益评价。
GMS health technology assessment Pub Date : 2009-12-14 DOI: 10.3205/hta000078
Falk Müller-Riemenschneider, Kathrin Damm, Charlotte Meinhard, Angelina Bockelbrink, Christoph Vauth, Stefan N Willich, Wolfgang Greiner
{"title":"Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease.","authors":"Falk Müller-Riemenschneider,&nbsp;Kathrin Damm,&nbsp;Charlotte Meinhard,&nbsp;Angelina Bockelbrink,&nbsp;Christoph Vauth,&nbsp;Stefan N Willich,&nbsp;Wolfgang Greiner","doi":"10.3205/hta000078","DOIUrl":"https://doi.org/10.3205/hta000078","url":null,"abstract":"<p><strong>Background: </strong>Coronary heart disease (CHD) is a common and potentially fatal malady with a life time prevalence of over 20%. For Germany, the mortality attributable to chronic ischemic heart disease or acute myocardial infarction is estimated at 140,000 deaths per year. An association between prognosis of CHD and lifestyle risk factors has been consistently shown. To positively influence lifestyle risk factors in patients with CHD, non-pharmaceutical secondary prevention strategies are frequently recommended and implemented.</p><p><strong>Objectives: </strong>The aim of this HTA (HTA = Health Technology Assessment) is to summarise the current literature on strategies for non-pharmaceutical secondary prevention in patients with CHD and to evaluate their medical effectiveness/efficacy and cost-effectiveness as well as the ethical, social and legal implications. In addition, this report aims to compare the effectiveness and efficacy of different intervention components and to evaluate the generalisability with regard to the German context.</p><p><strong>Methods: </strong>Relevant publications were identified by means of a structured search of databases accessed through the German Institute of Medical Documentation and Information (DIMDI). In addition, a manual search of identified reference lists was conducted. The present report includes German and English literature published between January 2003 and September 2008 targeting adults with CHD. The methodological quality of included studies was assessed according to pre-defined quality criteria, based on the criteria of evidence based medicine.</p><p><strong>Results: </strong>Among 9,074 publications 43 medical publications met the inclusion criteria. Overall study quality is satisfactory, but only half the studies report overall mortality or cardiac mortality as an outcome, while the remaining studies report less reliable outcome parameters. The follow-up duration varies between twelve and 120 months. Although overall effectiveness of non-pharmaceutical secondary prevention programs shows considerable heterogeneity, there is evidence for the long-term effectiveness concerning mortality, recurrent cardiac events and quality of life. Interventions based on exercise and also multicomponent interventions report more conclusive evidence for reducing mortality, while interventions focusing on psychosocial risk factors seem to be more effective in improving quality of life. Only two studies from Germany fulfill the methodological criteria and are included in this report. Additionally, 25 economic publications met the inclusion criteria. Both, quantity and quality of publications dealing with combined interventions are higher compared with those investigating single component interventions. However, there are difficulties in transferring the international results into the German health care system, because of its specific structure of the rehabilitation system. While international literatu","PeriodicalId":89142,"journal":{"name":"GMS health technology assessment","volume":"5 ","pages":"Doc16"},"PeriodicalIF":0.0,"publicationDate":"2009-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/aa/HTA-05-16.PMC3011286.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29644921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信